His primary areas of investigation include Internal medicine, Cardiology, Surgery, Myocardial infarction and Hazard ratio. Stroke, Heart failure, Atrial fibrillation, Cohort study and Risk factor are among the areas of Internal medicine where the researcher is concentrating his efforts. His Atrial fibrillation research integrates issues from Antiarrhythmic agent and Anesthesia.
His study in Cardiology is interdisciplinary in nature, drawing from both Placebo and Blood pressure, Diastole. His studies deal with areas such as Body mass index, Overweight, Odds ratio, Epidemiology and Population study as well as Surgery. His work in Myocardial infarction addresses subjects such as Antithrombotic, which are connected to disciplines such as Vitamin K antagonist.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Heart failure and Atrial fibrillation. Internal medicine is closely attributed to Surgery in his research. His work on Ejection fraction as part of general Cardiology research is frequently linked to In patient, bridging the gap between disciplines.
His research on Myocardial infarction often connects related topics like Trandolapril. His Heart failure research is multidisciplinary, incorporating perspectives in Heart disease and Metoprolol. He interconnects Epidemiology, Incidence, Retrospective cohort study, Pediatrics and Cohort in the investigation of issues within Cohort study.
Christian Torp-Pedersen spends much of his time researching Internal medicine, Cardiology, Heart failure, Atrial fibrillation and Confidence interval. In the subject of general Internal medicine, his work in Hazard ratio, Cohort study, Proportional hazards model and Myocardial infarction is often linked to In patient, thereby combining diverse domains of study. His research in Cardiology is mostly focused on ST segment.
Christian Torp-Pedersen has researched Heart failure in several fields, including Diabetes mellitus and Comorbidity. His research in Atrial fibrillation focuses on subjects like Cohort, which are connected to Retrospective cohort study. His Confidence interval research incorporates themes from Odds ratio, Demography and Poisson regression.
Internal medicine, Confidence interval, Cohort study, Heart failure and Atrial fibrillation are his primary areas of study. His research combines Cardiology and Internal medicine. Christian Torp-Pedersen has included themes like Odds ratio, Population study, Demography, Cardiopulmonary resuscitation and Sudden cardiac death in his Confidence interval study.
His work deals with themes such as Epidemiology, Incidence and Medical prescription, which intersect with Cohort study. In his study, Kidney disease is inextricably linked to Comorbidity, which falls within the broad field of Heart failure. His Atrial fibrillation study combines topics from a wide range of disciplines, such as Stroke, Complication and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Philip A. Poole-Wilson;Karl Swedberg;John G.F. Cleland;Andrea Di Lenarda.
The Lancet (2003)
A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Lars Køber;Christian Torp-Pedersen;Jan E. Carlsen;Henning Bagger.
The New England Journal of Medicine (1995)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
Marcus D. Flather;Salim Yusuf;Lars Køber;Marc Pfeffer.
The Lancet (2000)
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
Jonas Bjerring Olesen;Gregory Y H Lip;Morten Lock Hansen;Peter Riis Hansen.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom;Stuart J. Connolly;Jackie Bosch;Gilles R. Dagenais.
The New England Journal of Medicine (2017)
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Stefan H. Hohnloser;Martin van Eickels;Christophe Gaudin;Richard L. Page.
The New England Journal of Medicine (2009)
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population.
Tine Willum Hansen;Jan A. Staessen;Christian Torp-Pedersen;Susanne Rasmussen.
Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'.
Francesco U. S. Mattace-Raso;Albert Hofman;Germaine C. Verwoert;Jacqueline C. M. Witteman.
European Heart Journal (2010)
Increased Mortality after Dronedarone Therapy for Severe Heart Failure
Lars Køber;Christian Torp-Pedersen;John J.V. McMurray;Ole Gøtzsche.
The New England Journal of Medicine (2008)
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
Lars Køber;Jens J. Thune;Jens J. Thune;Jens C. Nielsen;Jens C. Nielsen;Jens Haarbo;Jens Haarbo.
The New England Journal of Medicine (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: